Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 in Major Depressive Disorder
NCT05376150Phase 2Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- May 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azetukalner in major depressive disorder (MDD) (3 arms), sponsored by Xenon Pharmaceuticals. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 6 weeks. Started May 2022; status: completed.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05376150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376150.